Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapid Micro Biosystems (RPID) Accounts Payables (2020 - 2025)

Rapid Micro Biosystems' Accounts Payables history spans 6 years, with the latest figure at $3.6 million for Q3 2025.

  • For Q3 2025, Accounts Payables rose 54.23% year-over-year to $3.6 million; the TTM value through Sep 2025 reached $3.6 million, up 54.23%, while the annual FY2024 figure was $2.5 million, 28.48% up from the prior year.
  • Accounts Payables for Q3 2025 was $3.6 million at Rapid Micro Biosystems, up from $3.3 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $5.4 million in Q4 2022 and bottomed at $1.2 million in Q1 2024.
  • The 5-year median for Accounts Payables is $2.6 million (2021), against an average of $2.8 million.
  • The largest annual shift saw Accounts Payables tumbled 63.75% in 2023 before it soared 126.37% in 2025.
  • A 5-year view of Accounts Payables shows it stood at $3.9 million in 2021, then surged by 37.63% to $5.4 million in 2022, then plummeted by 63.65% to $2.0 million in 2023, then rose by 28.48% to $2.5 million in 2024, then surged by 41.7% to $3.6 million in 2025.
  • Per Business Quant, the three most recent readings for RPID's Accounts Payables are $3.6 million (Q3 2025), $3.3 million (Q2 2025), and $2.6 million (Q1 2025).